Author:
Kropff Martin,Vogel Martin,Bisping Guido,Schlag Rudolf,Weide Rudolf,Knauf Wolfgang,Fiechtner Heinrich,Kojouharoff Georgi,Kremers Stephan,Berdel Wolfgang E.
Funder
Janssen Research and Development
Millennium Pharmaceuticals, Inc.
Publisher
Springer Science and Business Media LLC
Subject
Hematology,General Medicine
Reference39 articles.
1. Baz RC, Martin TG 3rd, Lin HY, Zhao X, Shain KH, Cho HJ, Wolf JL, Mahindra A, Chari A, Sullivan DM, Nardelli LA, Lau K, Alsina M, Jagannath S (2016) Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma. Blood 127:2561–2568
2. Ciolli S, Leoni F, Gigli F, Rigacci L, Bosi A (2006) Low dose Velcade, thalidomide and dexamethasone (LD-VTD): an effective regimen for relapsed and refractory multiple myeloma patients. Leuk Lymphoma 47:171–173
3. Davies FE, Wu P, Jenner M, Srikanth M, Saso R, Morgan GJ (2007) The combination of cyclophosphamide, velcade and dexamethasone induces high response rates with comparable toxicity to velcade alone and velcade plus dexamethasone. Haematologica 92:1149–1150
4. Dimopoulos MA, Orlowski RZ, Facon T, Sonneveld P, Anderson KC, Beksac M, Benboubker L, Roddie H, Potamianou A, Couturier C, Feng H, Ataman O, van de Velde H, Richardson PG (2013a) Retrospective matched-pair analysis of the efficacy and safety of Bortezomib plus dexamethasone versus Bortezomib monotherapy in patients (pts) with relapsed multiple myeloma (MM). Blood (ASH Annual Meeting Abstracts) 121:3177
5. Dimopoulos MA, Beksac M, Benboubker L, Roddie H, Allietta N, Broer E, Couturier C, Mazier MA, Angermund R, Facon T (2013b) Phase II study of bortezomib-dexamethasone alone or with added cyclophosphamide or lenalidomide for sub-optimal response as second-line treatment for patients with multiple myeloma. Haematologica 98:1264–1272
Cited by
17 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献